

PUBLICATIONS:

PATENTS:

UNITED STATES PATENT #5,891,858 issued April 6, 1999.

Title: Antisense Polynucleotide Inhibition of Epidermal Human Growth Factor Receptor Expression. Inventor: Marvin Rubenstein, Skokie, IL Assignee: Hektoen Institute for Medical Research

UNITED STATES PATENT #5,610,288 issued March 11, 1997.

Title: Antisense Polynucleotide Inhibition of Epidermal Human Growth Factor Sensitive Cells. Inventor: Marvin Rubenstein, Skokie, IL Assignee: Hektoen Institute for Medical Research

BOOK CHAPTERS:

1. Anderson, K.M. and Rubenstein, M.: Epithelial and Stromal Cell Separation from Rat Ventral Prostate: Cellular Physiological Studies. Second Pan American Congress of Andrology, p. 666, 1981.
2. Anderson, K.M., Baranowski, J. and Rubenstein M.: Epithelial and Stromal Cell Separation from Rat Ventral Prostate: Cellular-Physiologic Studies. In: Male Reproduction and Fertility. Raven Press, New York, p. 239, 1983.
3. Rubenstein, M., Guinan, P.D., Shaw, M.W. and Ablin, R.J.: Altered Helper-T, Suppressor-T Cell Representation in Those with Advanced Stage Prostatic Cancer. In: XXXII Colloquium: Protides of the Biological Fluids. Pergamon Press, Brussels, p. 901, 1984.
4. Shaw, M.W., McKiel, C.F., Ordonez, C., Rubenstein, M., Guinan, P.D. and Ablin, R.J.: Isolation and Characterization of Prostatic Tumor Effusions. In: XXXII Colloquium. Protides of the Biological Fluids. Pergamon Press, Brussels, p.941, 1984.
5. Shaw, M., McKiel, C.F., Rubenstein, M. and Guinan, P.D.: Effect of Tumor Necrosis Factor on a Rat Prostate Tumor Model. In: XXXV Colloquium: Protides of the Biological Fluids. Pergamon Press, Brussels, p. 351, 1987.
6. Rubenstein, M., Guinan, P.D., McKiel, C.F., Ray, P.S. and Shaw, M.W.: Evaluation of Adriamycin Chemotherapy and Polyamine Synthesis Inhibitor Alpha Difluoromethylornithine (DFMO) in the Treatment of a Transplantable Prostate Carcinoma of the Rat. In: XXXV Colloquium: Protides of the Biological Fluids, Pergamon Press, Brussels, p. 355, 1987.

7. Shaw, M.W., McKiel, C.F., Rubenstein, M. and Guinan, P.D.: Utilization of Monoclonal Antibodies to Detect Alterations in Leukocytic Subset Ratios Following Chemotherapy. In: XXXV Colloquium: Protides of the Biological Fluids. Pergamon Press, p 347, Brussels, 1987.
8. Guinan, P., Ray, R., Bhatti, and Rubenstein, M.: An Evaluation of Five Tests to Diagnose Prostate Cancer In: Prostate Cancer, Part A: Research, Volume 243A. Edited by G.P. Murphy, S. Khoury, C. Chatelain and L. Denis. Alan R. Liss, New York, p. 551, 1987.
9. Shaw, M., McKiel, C.F., Rubenstein, M and Guinan, P.D.: Effect of Tumor Necrosis Factor on a Rat Prostate Tumor Model. In: XXXV Colloquium: Protides of the Biological Fluids. Pergamon Press, Brussels, p. 351, 1987.
10. Grinis, G., Guinan, P., Lopez-Majano, V., Sansi, P., and Rubenstein, M.: Prostate Cancer: Monitoring Responses to Therapy - The Bone Scan. In: Diagnostic Ultrasound of the Prostate. Edited by M. Resnick, H., Watanabe and J.P. Karr. Elsevier, New York, p. 168, 1989.
11. Grinis, G., Lopez-Majano, V., Sansi, P., Sharifi, R., Rubenstein, M., and Guinan, P.: The Bone Scan "Flare Phenomenon", In: Advanced Prostate Cancer - The Effect of LHRH Agonist. IN: Clinical Aspects of Prostate Cancer. Edited by W.J. Catalona., D.S. Coffey and J.P. Kar. Elsevier, New York, p. 59, 1989.
12. Guinan, P., Richardson, C., Hanna, M., and Rubenstein, M.: BCG in the Management of Superficial Bladder Cancer. In: Therapeutic Progress in Urological Cancers. Edited by G.P. Murphy and S. Khoury. Alan R. Liss, New York, p. 447, 1989.
13. Rubenstein, M. Muchnik, S., Dunea, G., Chous, P., and Guinan, P.: Inoculation of Prostatic Tumors with Antisense Oligonucleotides against mRNA Encoding Growth Factors and Receptors. In: Recent Advances in Chemotherapy. Edited by J. Einhorn, C.K., Nord and S.R. Norby. American Society of Microbiology, Washington, D.C., p. 898-899, 1994.
14. Rubenstein, M. and Guinan, P.D.: Inhibition of the Autocrine Loop Regulated by the EGFR and TGF- Ligand. Edited by R. Anand, P. Smith and P. Warner. Ashley Publications Ltd., 1:1997.
15. Rubenstein, M.: Oligonucleotide & Gene Therapy-Based. In: Antisense Therapeutics with New Applications for Genomics. Edited by W. Hori and E.M. Nagle. IBC Library Series, Southborough, MA. 4:1-10, 1997.

16. Rubenstein, M., Mirochnik, Y., Guinan, P.: Delivery of Biotinylated Agents to Prostate Cancer Cells Utilizing Hybrid Monoclonal Antibodies. In: Oligonucleotide & Gene Therapy-Based Antisense Therapeutics with New Applications for Genomics. W. Hori (ed.) IBC Library Series, Southborough, MA, 1997, pp 4.2.1-4.2.10.
17. Rubenstein, M. and Guinan, P.: Inhibition of the Autocrine Loop Regulated by the Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor- α (TGF- α) Ligand. In: Emerging Therapeutic Targets. R. Anand, P. Smith and P. Warne (eds) Ashly Publications Ltd, London, 1997 pp 165-168.

PAPERS:

1. Rubenstein, M., Giacomoni, D. and Pachman, L.M.: Effect of Sodium Salicylate on Hamster Cells In Vitro. Journal of Pharmaceutical Sciences, 65:756, 1976.
2. Anderson, K.M., Rubenstein, M. and Seed, T.M.: In Vivo Expression of a C-Type RNA Virus in Rat Ventral Prostate Epithelial Cells. Biochemical and Biophysical Research Communications, 86:402, 1979.
3. Anderson, K.M., Bass, B., Rubenstein, M. and Sacharides, T.: Nuclear Protein Synthesis at Permissive and Non-Permissive Temperatures in a Chinese Hamster Ovary Cell Line with a Temperature-Sensitive Defect in Cytoplasmic Non-Mitochondrial Protein Synthesis. Experimental Cell Research, 121:191, 1979.
4. Rubenstein, M. and Anderson, K.M.: Isolation of Viable Rat Ventral Prostate Epithelial and Nonepithelial Cells. Endocrinology, 106:530, 1980.
5. Seed, T.M., Rubenstein, M. and Anderson, K.M.: Early Effects of Castration and Replacement of Androgen on the Expression of Retro-Virus-Like Particles in Rat Ventral Prostate Epithelial Cells. Proceedings of the Society for Experimental Biology and Medicine, 169:470, 1982.
6. Rubenstein, M., Anderson, K.M., and Sky-Peck, H.: Mithramycin Impairs the Release of Ca From Bone Induced by Prostaglandin E₂ or Multiple Myeloma Sera. Oncology, 39:7277, 1981.
7. Rubenstein, M. and Anderson, K.M.: Effect of Castration and Replacement of Androgen on Separation of Rat Ventral Prostate Cells by Ficoll Gradient Centrifugation. Clinical Physiology and Biochemistry, 1:27, 1983.
8. Anderson, K.M., Baranowski, J., Economou, S.G. and Rubenstein, M.: A Qualitative Analysis of Acidic Protein Associated with Regressing, Growing or Dividing Rat Ventral Prostate Cells. The Prostate, 4:151-165, 1983.

9. Shaw, M.W., Ablin, R.J., Miserec, P., Guinan, P.D. and Rubenstein, M.: Characterization of the Mononuclear Cell Population in the Peripheral Blood of Patients with Prostate Cancer. *IRCS Medical Science*, 11:714, 1983.
10. Shaw, M.W., Ablin, R.J., Guinan, P.D., Rubenstein, M. and Miserec, P.: Characterization of the Mononuclear Cell Populations in Primary Tumour Infiltrates and Peripheral Blood of Patients with Genitourinary Cancer. *IRCS Medical Science*, 11:734, 1983.
11. Shaw, M.W., Ablin, R.J., McKiel, C.F., Rubenstein, M. and Guinan, P.D.: Characterization of Tumour Effusions of the Dunning R-3327 Rat Prostatic Adenocarcinoma. *IRCS Medical Science*, 12:640, 1984.
12. Rubenstein, M., Shaw, M. S., Ablin, R.J., Guinan, P.D. and McKiel, C.F.: Further Evaluation and Characterization of the Mononuclear Cell Population of Patients with Prostate Cancer *IRCS Medical Science*, 12:761, 1984.
13. Braun, D.P., Harris, J.E. and Rubenstein, M.: Relationship of Arachidonic Acid Metabolism to Indomethacin-Sensitive Immunoregulatory Function and Lymphocyte PGE Sensitivity in Peripheral Blood Mononuclear Cells of Disseminated Solid Tumour Cancer Patients. *Journal of Immunopharmacology*, 6(3) 227, 1984.
14. Shaw, M.W., Ablin, R.J., Ray, P., Rubenstein, M., Guinan, P.D. and McKiel, C.F.: Immunobiology of the Dunning R3327 Rat Prostate Adenocarcinoma Sublines: Plasma and Tumor Effusion Prostaglandins. *Immunology of Reproduction*, Tel Aviv, Israel pp. 21-25, 1984.
15. Rubenstein, M., Shaw, M.W., Bhatti, R.A., Habibi, H. and Guinan, P.D.: The Effect of Low Dose Cyclophosphamide and Immunologic Exposure Upon Growth of Established R-3327-G Subline: Rat Prostate Adenocarcinomas. *The Prostate*, 7:151. 1985.
16. Rubenstein, M.D. Shaw, M.W., Stobnicki, M., Ablin, R.J. and Guinan, P.D.: The Effect of Hormone Therapy on Peripheral Blood Leukocytic Subset Distributions in Stage D Prostatic Cancer Patients. *Urological Research*, 13:67, 1985.
17. Shaw, M.W., Ablin, R.J., Ray, P., Rubenstein, M., Guinan, P.D. and McKiel, C.F.: Immunobiology of the Dunning R3327 Rat Prostate Adenocarcinoma Sublines: Plasma and Tumor Effusion Prostaglandins. *American Journal of Reproductive Immunology and Microbiology*, 8:77, 1985.
18. Clayton, M., Rubenstein, M., Shaw, M. and Guinan, P.: Prostaglandin E₂ Activity in the Microenvironment of Prostate Tumors. *Surgical Forum*, 36:644, 1985.

19. Rubenstein, M., Ablin, R.J., Shaw, M.W., Guinan, P.D. and McKiel, C.F.: Distribution of Mononuclear Cells in the Peripheral Blood of Patients with Prostate Cancer. *Tumor Diagnostik & Therapie*, 6:177, 1985.
20. Shaw, M.W., Ablin, R.J., Rubenstein, M., McKiel, C.F. and Guinan, P.D.: Characterization of Mononuclear Cells in the Peripheral Blood and Primary Tumour Infiltrates of Patients with Stage D Prostate Cancer. *Tumor Diagnostik & Therapie*, 6:223, 1985.
21. Guinan, P., Rubenstein, M., Ray, P., Bush, I.M., Feinstein, C. and Shaw, M.: New Approaches to Prostate Coancer Therapy. *Proceeding of the Institute for Medicine of Chicago*, 38:83, 1985.
22. Guinan, P., Habibi, H., Ray, P., Wang, E. and Rubenstein, M.: Prostate Cancer, *Proceedings of the Institute for Medicine of Chicago*, 38:83, 1985.
23. Shaw, M.W., Bhatti, R., McKiel, C.F., Guinan, P.D. and Rubenstein, M.: Leukocytic Subset Distributions of Spleen. Cells Obtained from Rats Bearing Variants of the Dunning Prostatic Adenocarcinoma. *Journal of Urology*, 135:159, 1986.
24. Anderson, K.M. and Rubenstein, M.: In Vitro Stimulation by Prostate Extracts of Rat Ventral Prostate Stromal and Epithelial Cell Division. *The Prostate*, 8:227, 1986.
25. Anderson, K.M. and Rubenstein, M.: Rat Ventral Prostate Lysis at 2°C. *Clinical Physiology and Biochemistry*, 4:229, 1986.
26. Rubenstein, M., Shaw, M.W., Dubin, A., Ray, P. S. and Guinan, P.D.: Adherent Spleen Cell Production of E Series Prostaglandins in Rats Bearing Variants of the R3327 Dunning Prostatic Adenocarcinoma: Effect of Cyclophosphamide. *Journal of Immunopharmacology*, 8(2):145, 1986.
27. Rubenstein, M.D., Shaw, M.W., McKiel, C.F., Ray, P.S. and Guinan, P.D.: Immunoregulatory Markers in Rats Carrying Dunning R3327 H, G, and MAT-LyLu Prostatic Adenocarcinoma Variants. *Cancer Research*, 47:178, 1987.
28. Guinan, P. and Rubenstein, M.: Methods of Early Diagnosis in Genitourinary Cancer. *Cancer Supplement*, 60:668, 1987.
29. Shaw, M., Ray, P., Rubenstein, M. and Guinan, P.: Lymphocyte Subsets in Urologic Cancer Patients. *Urological Research*, 15:181, 1987.
30. Shaw, M.W., Guinan, P., McKiel, C.F., Dubin, A. and Rubenstein, M.: Combination Therapy Using Polyamine Synthesis Inhibitor Alpha-Difluoromethylornithine and Adriamycin in

Treatment of Rats Carrying the Dunning R3327 MAT-LyLu Prostatic Adenocarcinoma. *The Prostate*, 11:87, 1987.

31. Shaw, M.W., Rubenstein, M., Dubin, A., McKiel, C.F. and Guinan, P.D.: The effect of Cyclophosphamide on Leukocytic Subset Distributions in Rats Carrying the Dunning R3327 Mat-LyLu Prostatic Adenocarcinoma. *The Prostate*, 11:117, 1987.
32. Shaw, M.W., Guinan, P.D., Dubin, A., McKiel, C.F. and Rubenstein, M.: Administration of Recombinant Tumor Necrosis Factor to Rats Bearing the Dunning R3327 MAT-LyLu Prostatic Adenocarcinoma. *Clinical Physiology and Biochemistry*, 5:315, 1987.
33. Guinan, P., Crispen, R. and Rubenstein, M.: BCG in the Management of Superficial Bladder Cancer: A Review. *J. of Urology*, 30(6):515, 1987.
34. Rubenstein, M., Guinan, P., McKiel, C.F. and Dubin, A.: Review of Acid Phosphatase in the Diagnosis and Prognosis of Prostatic Cancers. *Clinical Physiology and Biochemistry*, 6:241, 1988.
35. Rubenstein, M., Shaw, M.W., Dubin, A., McKiel, C.F. and Guinan, P.D.: Effect of BCG Upon Functional and Phenotypic Immune Markers in Rats Bearing the Dunning R3327 MAT-LyLu Prostatic Adenocarcinoma. *Immunopharmacology and Immunotoxicology*. 10(4):579, 1988.
36. Guinan, P., Ray, P. and Rubenstein, M.: Prostatic Ultrasound in Follow-up of Prostatic Disease. *J. of Urology*, 31:275. 1988.
37. Gradle, C., Ratajczak, H., Fresco, R., Black, M.B., Rubenstein, M., and Thomas, P.: Definition of the Pulmonary Antibody Response to Ovalbumin Following Local Challenge in Systemically Immunized Rats (42707). *Proceedings of the Society for Experimental Biology and Medicine*, 188:61, 1988.
38. Rubenstein, M., Shaw, M., Ray, V., Dubin, A., McKiel, C.F. and Guinan, P.: Application of Immunohistologic Staining to Develop a Malignant Index to Aid in Distinguishing Benign from Malignant Prostatic Tissue. *The Prostate*, 14:383, 1989.
39. Guinan, P., Shaw, M., Targonski, P., Ray, V. and Rubenstein, M.: Evaluation of Cytokeratin Markers to Differentiate between Benign and Malignant Prostatic Tissue. *Journal of Surgical Oncology*, 42:175, 1989.
40. Guinan, P., Grinis, G., Kester, S., Targonski, P. and Rubenstein, M.: Diagnosis and Staging of Prostate Cancer. *Proceedings of the Institute for Medicine of Chicago*, 42:54, 1989.

41. Grinis, G., Shaw, M., Targoniski, P. and Rubenstein, M., Guinan, P.: Does Cytoreductive Surgery Impede the Metastatic Process? *Surgical Forum*, 40:682, 1989.
42. Siami, P., Chinn, S., Clayton, M., Ray, V., Rubenstein, M. and Guinan, P.: BCG in Management of Transitional Cell Carcinoma Invasive to Prostate. *Journal of Urology*, 135:381-382, 1989.
43. Johnson, M., Shaw, M., Rubenstein, M. and Guinan, P.: Effect of Early and Delayed Difluoromethylornithine Pretreatment upon Cyclophosphamide Chemotherapy. *Clin. Physiol. Biochem.* 8:11-15, 1990.
44. Chou, P., Ray, V., Shaw, M., Rubenstein, M. and Guinan, P.: An Immunohistologic Characterization of Human Prostatic Atypical Hyperplasia. *Urol. Res.* 18:193-196, 1990.
45. Rubenstein, M., Muchnik, S., Chet, M., Shaw, M., Dubin, A. and Guinan, P.: Efficacy of Immunopriming prior to Isolation of Tumor Infiltrating Lymphocytes for Use in Adoptive Immunotherapy. *Immunotoxicol.* 2:583-594, 1990.
46. Shaw, M., McKiel, C.F., Ray, V. and Rubenstein, M.: Characterization of Cellular Infiltrates in the Rat Urinary Bladder Following BCG and Thiotepa Intravesical Therapy. *Journal of Surgical Oncology*, 46:48-52, 1991.
47. Grinis, G., Targonski, P., Shaw, M., Rubenstein, M. and Guinan, P.: Cytoreductive Surgery Impedes Metastasis and Enhances the Immune Response: A Preliminary Report. *Journal of Surgical Oncology*, 46:48-122-126, 1991.
48. Guinan, P., Moorman, C. and Rubenstein, M.: Prostate Cancer: Increasing Public Health Problem Relative to Lung Cancer. *Proc. Inst. Med. Chgo.*, 44:24-26, 1991.
49. Knudson, G., Grinis, G., Lopez-Majano, V., Sansi, P., Targonski, P., Rubenstein, M., Sharifi, R. and Guinan, P.: Bone Scan as a Stratification Variable in Advanced Prostate Cancer. *Cancer*, 68:316-320, 1991.
50. Rubenstein, M., Muchnik, S., Chet, M., Shaw, M.W., McKiel, C.F. and Guinan, P.: Tumor Infiltrating Lymphocytes: The Effect of Bacillus Calmette Guerin on Helper/Suppressor-T Cell Ratios of Treated and Untreated Tumors. *Journal of Urology*, 146:1650-1653, 1991.
51. Rubenstein, M., Shaw, M., Targonski, P., McKiel, C.F., Dubin, A. and Guinan, P.: GM-DSF Restoration of a Differentiated (Growth Factor-Regulated) Phenotype in an Anaplastic Tumor. *Urology Res.*, 19:309-312, 1991.

52. Shaw, M., McKiel, C.F., Ray, V., Rubenstein, M. and Guinan, P.: Characterization of Cellular Infiltrated in the Rat Urinary Bladder Following BCG and Thiotepa Intravesical Therapy. *Journal of Surgical Oncology*, 46:48-52, 1991.
53. Frank, W., Stuhldreher, D., Muchnik, S., Shaw, M., Chou, P., Rubenstein, M., Ray, P. and Guinan, P.: Microsurgical Approach to the Abdominal Thoracic Duct in the Rat: Considerations in the Collection of Lymphocytes. *Microsurgery*, 131:332-334, 1992.
54. Frank, W. Sharifi, R., Ray, P. and Rubenstein, M.: University of Illinois Hospitals Testicular Cancer Experience. *Proceedings Inst. Med. Chgo.*, 45:62, 1992.
55. Rubenstein, M., Shaw, M., Targonski, P., McKiel, C.F., Dubin, A. and Guinan, P.: Coordinate Loss of Growth Regulatory Factors Following Castration of Rats Carrying the Dunning R3327 Prostatic Tumor. *Clin. Physiol. Biochem.*, 45:90, 1992.
56. Stuhldreyer, D., Frank W., Shaw, M., Muchnik, S., Hussein, N., Rubenstein, M. and Guinan, P.: The Effect of BCH on Thoracic Duct Lymphocytes. *Immunol. Invest.*, 21:613-621, 1992.
57. Frank, W., Guinan, P., Stuhldreher, D., Saffrin, R., Ray, P. and Rubenstein, M.: Renal Cell Carcinoma: The Size Variable. *J. Surg. Oncol.*, 54:163-166, 1993.
58. Guinan, P., Shaw, M. and Rubenstein, M.: Immunopriming of Tumor Infiltrating Lymphocytes with Neoadjuvant Cyclophosphamide. *Immunol. Invest.* 22:87-93, 1993.
59. Guinan, P., Firfer, R., Targonski P., and Rubenstein, M.: Bilateral Orchiectomy in the Management of Stage D-2 Prostate Cancer. *Intl. Surg.*, 78:73-75. 1993.
60. Guinan, P., Bush, I., and Rubenstein, M.: Detecting Prostate Cancer in Primary-Care Medicine. *Chgo. Med.* 96:32-35, 1993.
61. Guinan, P., Reyes, H. and Rubenstein, M.: Cook County Hospital and the Chicago School of Surgery. *Chgo. Med.*, 96:14-18, 1993.
62. Rubenstein, M., Muchnik, S., Gaber, S.L., Arruda, J.A.L. and Dunea, G.: Differential Effect of Xanthopterin and Biopterin on Cell Growth. *Int. J. Biochem.*, 12:1873-1880, 1993.
63. Bridges, P., Shaw, M., Rubenstein, M. and Guinan, P.: Accelerated Growth of Orthotopically Placed Prostate Tumors. *Surg. Forum.* 45:809-810, 1994.
64. Guinan, P., Frank, W., Saffrin, R. and Rubenstein, M.: Staging and Survival of Patients with Renal Cell Carcinoma. *Sem. In Surg. Oncol.*, 10:47-50, 1994.

65. Rubenstein, M., Dunea, G. and Guinan, P.: Growth Factor Deprivation Therapy Utilizing Antisense Oligonucleotides. *Drug News and Perspectives*, 7:517-5224, 1994.
66. Frank, W., Stuhldreher, D., Saffrin, R., Shott, S., Rubenstein, M. and Guinan, P.: Stage IV Renal Cell Carcinoma. *J. Urol.* 152:1998-1999, 1994.
67. Guinan, P., Friedell, M.T., Rubenstein, M. and Steigman, F.: Research Giant Celebrates 50 Years. *Chicago Medicine*, 97:12-15, 1994.
68. Guinan, P. and Rubenstein, M.: Prostate Cancer Immunotherapy. *Drugs of Today*, 31:135-140, 1995.
69. Brown, J., Didomenico, D., Shaw, M., Rubenstein, M. and Guinan, P.: The Interferon Inducer Bropirimine Complements Prostatectomy in an Orthotopic Animal Model. *Surg. Forum XLVI*, 785-787m 1995.
70. Bush, I.M., Guinan, P., Rubenstein, M. and Ray, P.: A History of Urology at Cook County Hospital. A Focus for Chicago, the Midwest and the United States. *Chicago Medicine*, 98:8-11, 1995.
71. Guinan, P., Saffrin, R., Stuhldreher, D., Frank, W. and Rubenstein, M.: Renal Cell Carcinoma: Comparisons of the TNM and Robson Stage Groupings. *J. Surg. Oncol.* 59:186-189, 1995.
72. Guinan, P.D., Rubenstein, M. and Imperato, J.P.: Cancer Conferences in Illinois: Compliance with COG Guidelines. *Bull. Amer. Coll. Surg.* 80:24-27, 1995.
73. Guinan, P. and Rubenstein, M.: Prostate Cancer Therapy in the Age of Molecular Biology. *Drug News and Perspectives*, 8:525-530, 1995.
74. Guinan, P. and Rubenstein, M.: BCGG and Biological Response Modifiers in Prostate Cancer. *Cancer Invest.* 13:48-49, 1995.
75. Rubenstein, M., Saffrin, R., Shaw, M., Muchnik, S. and Guinan, P.: Orthotopic Placement of the Dunning R3327 AT-3 Tumor in the Copenhagen X Fischer Rat. *The Prostate*, 27:148-153, 1995.
76. Saffrin, R., Phillips, C., Guinan, P. and Rubenstein, M.: The Impact of Transrectal Ultrasound on Stage Migration in a Predominantly African-American Population. *J. Natl. Med. Assoc.*, 87:759-761, 1995.
77. Saffrin, R., Chou, P., Ray, V., Shaw, M., Rubenstein, M. and Guinan, P.: Suramin as adjuvant therapy with radical prostatectomy. *The Prostate* 28:325-327, 1996.

78. Rubenstein, M., Mirochnik, Y., Chow, P. and Guinan, P.: Antisense Oligonucleotide Intralesional Therapy of Human PC-3 Prostate Tumors Carried in Athymic Nude Mice. *J. Surg. Oncol.*, 62:194-200, 1996.
79. Lievano, G., Mirochnik, Y., Rubenstein, M., Shaw, M. and Guinan, P.: Antitumor effect of CPT-11, a New Derivative of Camptothecin, against Human Prostate Cancer (PC-3) In Vitro and Prostate Rat Tumor (AT-3) In Vivo. *Meth. Find. Exp. Clin. Pharmacol.* 18:659-662, 1996.
80. DiDomenico, D., Bridges, P., Sharifi, R., Rubenstein, M. and Guinan, P.: Survival of Mexican-American Males with Seminoma. *Rev. Invest. Clin.* 49:93-96, 1997.
81. Guinan, P., Stuhldreher, D., Frank, W. and Rubenstein, M.: Report of 337 Patients with Renal Cell Carcinoma Emphasizing 110 with Stage IV Disease and Review of the Literature. *J. Surg. Oncol.* 64:295-298, 1997.
82. Guinan, P., DiDomenico, D., Brown, J., Shaw, M., Sharifi, R., Ray, V., Shott, S. and Rubenstein, M. The Effect of Androgen Deprivation on Malignant and Benign Prostate Tissue. *Med. Oncol.* 14:145-152, 1997.
83. Lievano, G., DiDomenico, D., Brown, J., Bridges, P., Rubenstein, M., Shaw, M. and Guinan, P.: Bropiramine as Neoadjuvant Therapy Decreases Residual Disease and expression of Markers PCNA and TGF-b1 in a Rat Orthotopic Prostate Adenocarcinoma. *Meth. Find. Exp. Clin. Pharmacol.* 19:261-267, 1997.
84. Rubenstein, M., Chou, P., Mirochnik, Y. and Guinan, P.: Enhanced Expression of bcl-2 following Antisense Oligonucleotide Mediated Growth Factor Deprivation. *Med. Oncol.* 14:23-29, 1997.
85. Rubenstein, M., Mirochnik, Y., Ray, V. and Guinan, P.: Lack of Toxicity Associated with the Systematic Administration of Antisense Oligonucleotides for Treatment of Rats Bearing LNCaP Prostate Tumors. *Med. Oncol.* 14:131-136, 1997.
86. Rubenstein, M., Mirochnik, Y., Chou, P. and Guinan, P.: Growth Factor Deprivation Therapy of Hormone Insensitive Prostate and Breast Cancers Utilizing Antisense Oligonucleotides. *Meth. Find. Clin. Pharmacol.* 20:825-831, 1998.
87. Guinan, P., Shaw, M., Mirochnik, Y., Slobodskoy, L., Ray, V. and Rubenstein, M.: Paclitaxel is More Effective than thalidomide in Inhibiting LNCaP Tumor Growth in a Prostate Cancer Model. *Meth. Find. Exp. Clin. Pharmacol.* 20:739-742, 1998.

88. Shaw, M., Ratanawong, S., Chou, P., Ray, V., Mirochnik, Y., Slobodskoy, L., Rubenstein, M. and Guinan, P.: Paclitaxel, bropiramine and linomide: Effect on Growth Inhibition in a Murine Prostate Cancer Model by Different Growth Regulatory Mechanisms. *Methods Find. Exp. Clin. Pharmacol.* 20:111-114, 1998.
89. Uzoaru, I., Rubenstein, M., Mirochnik, Y., Slobodskoy, L., Shaw, M. and Guinan, P.: An Evaluation of the Markers p53 and Ki-67 for their Predictive Value in Prostate Cancer. *J. Surg. Oncol.* 67:33-37, 1998.
90. Rubenstein, M., Shaw, M., Mirochnik, Y., Slobodskoy, L., Glick, R., Lichtor, T., Chou, P. and Guinan, P.: In Vivo Establishment of T98G Human Glioblastoma. *Methods Find. Exp. Clin. Pharmacol.* 21:391-393, 1999.
91. Rubenstein, M. and Guinan, P.: A Review of Various Antisense Oligonucleotide Therapeutic Approaches for Prostate Cancer. *The Prostate Journal* 2:179-188, 2000.
92. Shaw, M., Elterman, L., Rubenstein, M., McKiel, C.F. and Guinan, P.: Changes in Radical Prostatectomy and Radiation Therapy Rates for African-Americans and Whites. *J. Natl. Med. Assoc.* 92:281-284, 2000.
93. Rubenstein, M., Glick, R., Lichtor, T., Mirochnik, Y., Chou, P. and Guinan, P.: Treatment of the T98G Glioblastoma Cell Line with Antisense Oligonucleotides Directed Toward mRNA Encoding Transforming Growth Factor-alpha and the Epidermal Growth Factor Receptor. *Med. Oncol.* 18:121-130, 2001.
94. Rubenstein, M., Mirochnik, Y., Slobodskoy, L. and Guinan, P.: Biotinylation of Antisense Oligonucleotides Does Not Alter Lipofectin Enhanced Cellular Uptake in Prostate Cancer Cell Lines. *Meth. Find. Clin. Pharmacol.* 23:487-490, 2001.
95. Rubenstein, M., Slobodskoy, L., Mirochnik, Y. and Guinan, P.: Backbone modification alters the efficacy of antisense oligonucleotides directed against mRNA encoding either TGF- α or EGFR in the treatment of prostate cancer cell lines. *Methods Find. Exp. Clin. Pharmacol.* 24:649-652, 2002.
96. Rubenstein, M., Slobodskoy, L., Mirochnik, Y. and Guinan, P.: Inhibition of PC-3 prostate cancer cell growth in vitro using both antisense oligonucleotides and taxol. *Med. Oncol.* 20:29-35, 2003.
97. Rubenstein, M., Tsui, P., Guinan, P.: A review of antisense oligonucleotides in the treatment of human disease. *Drugs of the Future* 29:893-909, 2004.

98. Tsui, P., Rubenstein, M., Guinan, P.: Synergistic effects of combination therapy employing antisense oligonucleotides with traditional chemotherapeutics in the PC-3 prostate cancer model. *Med. Oncol.* 21:339-348, 2004.
99. Mirochnik, Y., Rubenstein, M. and Guinan, P.: Two constructed antibody derived vehicles for targeting oligonucleotides to prostate tumors expressing prostate specific antigen. *Drug Delivery* 11:161-167, 2004.

Reviewed in DailyUpdates of August 23, 2004: leaddisc@LeadDiscovery.CO.UK

100. Anderson, K.M., Rubenstein, M., Alrefai, W.A., Dudeja, P., Tsui, P., Harris, J.E.: Acute changes in U937 nuclear Ca^{2+} preceding type 1 “apoptotic” programmed cell death due to MK 886. *Anticancer Res.* 24:2601-2616, 2004.
101. Anderson, K.M., Rubenstein, M., Alrefai, W.A., Dudeja, P., Tsui, P., Harris, J.: Acute changes in U937 nuclear Ca^{2+} preceding type 1 “apoptotic” programmed cell death due to mk 886. *Anticancer Res.* 24:2601-16, 2004.
102. Rubenstein, M., Tsui, P., Guinan, P.: Construction of a bispecific antisense oligonucleotide containing multiple binding sites for the treatment of hormone insensitive prostate tumors. *Med. Hypotheses* 65:905-907, 2005.
103. Tsui, P., Rubenstein, M., Guinan, P.: Correlation between PSMA and VEGF expression as markers for LNCaP tumor angiogenesis. *Biomedicine and Biotechnology* 3:287-290, 2005.
104. Tsui, P., Rubenstein, M., Guinan, P.: siRNA is not more effective than a first generation antisense oligonucleotide when directed against EGFR in the treatment of PC-3 prostate cancer. *In vivo* 19:653-656, 2005.
105. Anderson, K.M., Rubenstein, M., Tsui, P., Harris, J.E.: Disparate forms of MK 886-induced programmed death in BCL-2 (+) blood and BCL-2 (-) solid cancer cells and a putative “nuclear” Ca^{2+} channel: “soil” trumps “seed”? *Med. Hypoth.* 64:307-311, 2005.
106. Anderson, K.M., Rubenstein, M., Alrefai, W.A., Dudeja, P., Tsui, P., Guinan, P., Harris, J.E.: Reactive oxygen species and redox-induced programmed cell death due to MK 886: Cells (“soil”) “Trump” agent (“seed”). *In vivo* 19:109-118, 2005.
107. Rubenstein, M., Tsui, P., Guinan, P.: Bispecific antisense oligonucleotides with multiple bindings sites for the treatment of prostate tumors and their applicability to combination therapy. *Meth. Find. Clin. Pharmacol.* 28:515-518, 2006.

108. Rubenstein, M., Anderson, K.M., Tsui, P., Guinan, P.: Synthesis of branched antisense oligonucleotides having multiple specificities: Treatment of hormone insensitive prostate cancer. *Med. Hypoth.* 67:1375-1380, 2006.
109. Anderson, K.M., Tsui, P., Guinan, P., Rubenstein, M.: The proliferative response of HeLa cells to 2-deoxy-D-glucose under hypoxic or anoxic conditions: An analogue for studying some properties of *in vivo* solid cancers. *Anticancer Res.* 26:4155-4162, 2006.
110. Anderson, K.M., Tsui, P., Rubenstein, M., Guinan, P.: To what extent are the “sets” of biologic properties expressed by hypoxic cancer cells and by cancer “stem” cells equivalent, intersecting, disjoint or complementary? Some implications for the design of cancer therapies. *Med. Hypotheses* 68:166-168, 2007.
111. Mirochnick, Y., Rubenstein, M., Guinan, P.: Targeting of biotinylated oligonucleotides to prostate tumors with antibody-based delivery vehicles. *J. Drug Targeting* 15:342-350, 2007.
112. Rubenstein, M., Tsui, P., Guinan, P.: Bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate cancer. *Med. Oncol.* 24:189-196, 2007.

Reviewed in DailyUpdates of November 15, 2007: leaddisc@LeadDiscovery.CO.UK

113. Rubenstein, M., Tsui, P., Guinan, P.: Combination chemotherapy employing bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors. *Med. Oncol.* 24: 372-378, 2007.

Reviewed in DailyUpdates of November 15, 2007: leaddisc@LeadDiscovery.CO.UK

114. Anderson, K.M., Darweesh, M., Jajah, A., Tsui, P., Guinan, P., Rubenstein, M.: Does homeobox-related “Positional” genomic information contribute to implantation of metastatic cancer cells at non-random sites? *Anticancer Res.* 27: 2141-2153, 2007.
115. Anderson, K.M., Jajah, A., Guinan, P., Tsui, P., Rubenstein, M.: Do intra-tumor alkaline micro-regions represent additional therapeutically privileged sites? *Med. Hypotheses* 70:1193-1196, 2008.
116. Rubenstein, M., Tsui, P., Guinan, P.: Treatment of MCF-7 breast cancer cells employing mono- and bispecific antisense oligonucleotides having binding specificity toward proteins associated with autocrine regulated growth and BCL-2. *Med. Oncol.* 25: 182-186, 2008.

Reviewed in DailyUpdates of November 30, 2007: leaddisc@LeadDiscovery.CO.UK

117. Rubenstein, M., Tsui, P., Guinan, P.: Multigene targeting of signal transduction pathways for the treatment of breast and prostate tumors. Comparisons between combination therapies employing bispecific oligonucleotides with either Rapamycin or Paclitaxel. (In Press: Med. Oncol.)

PUBLISHED ABSTRACTS

1. Rubenstein, M. and Anderson, K.M.: Separation of Androgen-Binding Epithelial Cells from Connective Tissue Cells of the Rat Ventral Prostate. *Journal of Cell Biology*, 79:188a, 1978.
2. Anderson, K.M., Rubenstein, M. and Seed, T.M.: Morphologic Evidence for C-type RNA Viruses in Isolated Rat Ventral Prostate Epithelial Cells. *Biophysical Journal*, 25:160a, 199/
3. Anderson, K.M., Rubenstein, M. and Seed, T.M.: In Vivo Expression C-Type RNA Virus in Rat Ventral Prostate Epithelial Cells. *Proceedings of the American Association for Cancer Research*, 20:996a, 1979.
4. Anderson, K.M., Rubenstein, M. and Taylor, S.G.: Evidence for a Prostate-Specific Cell Lytic Factor Active at Low Temperature. *Proceedings of the American Association for Cancer Research*, 20:598a, 1979.
5. Rubenstein, M. and Anderson, K.M.: Distribution on an Isokinetic Gradient of Cells from Dissociated Rat Ventral Prostates of Normal, Castrated and Hormone-Treated Rats. *Endocrinology*, 106-20a, 1980.
6. Rubenstein, M., Sky-Peck, H. and Anderson, K.M.: The Use of Mithramycin to Impair Release from Bone of Ca Induced by Prostaglandin E2 and Multiple Myeloma Sera. *Proceedings of the American Association for Cancer Research*, 21:66a, 1980.
7. Anderson, K.M., Baranowski, J. and Rubenstein, M.: Further Studies of Nuclear Protein Synthesis in a Temperature-Sensitive CHO Line. *Federation Proceedings*, 39:1389a, 1980
8. Rubenstein, M. and Anderson, K.M.: Evidence for a Rat Prostate-Specific Cell Lysis Active at 2°C. *Journal of Cell Biology*, 87:703a, 1980
9. Rubenstein, M., Braun, D.P. and Harris, J.E.: Abnormal Prostaglandin Metabolism in Cancer Patient Monocytes. *Clinical Research*, 29737a, 1981.

10. Rubenstein, M. and Anderson, K.M.: Differential Suppression of Fibroblasts and the Growth of Epithelioid Cells from a Suspension of Single Rat Ventral Prostate Cells. *Biophysical Journal*, 37:267a, 1982.
11. Rubenstein, M. and Anderston, K.M.: A High Molecular Weight Heat Sensitive Cell Stimulatory Activity from Rat Ventral Prostate. *Journal of Cell Biology*, 95:9062a, 1982
12. Rubenstein, M., Bonomi, P., and Anderson, K.M.: Detection of Rat Prostate Stromal and Epithelioid Cell Growth Inhibitors in Acid-Alcohol or Chloroform-Extracted Dunning Adenocarcinoma and in a Metastatic Human Colon Cancer. *Proceedings of the American Association for Cancer Research*, 23:934a, 1982.
13. Shaw, M.W., Guinan, P.D., Rubenstein, M., Ortotano, V. and Ablin, R.J.: Identification and Quantification of Mononuclear Cells in the Peripheral Blood and Tumor Infiltrates of Patients with Genitourinary Cancer. *Clinical Research*, 31:742a, 1983.
14. Shaw, M.W., Rubenstein, M., Stuart, R., Guinan, P.D. and Ablin, R.J.: Subpopulation of Lymphocytes in the Peripheral Blood of Patients with Carcinoma of the Prostate. *Clinical Research*, 31:742a, 1983.
15. Shaw, M.W., Ablin, R.J., Rubenstein, M., Stuart, R. And Guinan, P.D.: Lymphocyte Subpopulations in Patients with Prostate Cancer. *Proceeding of Oncodevelopment Biology and Medicine*. X1 Annual Meeting. Stockholm, Sweden, 1983.
16. Rubenstein, M., Guinan, P.D., Shaw, M.W. and Ablin, R.J.: Altered Helper-T, Suppressor-T Cell Representation in Those with Advanced Prostatic Cancer. *Proceedings of the XXX II Colloquium: Protides of the Biological Fluids Brussels*, 1983.
17. Shaw, M.W., McKiel, C.F., Ordonez, C., Rubenstein, M., Guinan, P.D. and Ablin, R.J.: Isolation and Characterization of Prostatic Tumor Effusions. *Proceedings of the XXXII Colloquium: Protides of the Biological Fluids*. Brussels, 1983.
18. Baranowski, J., Rubenstein, M. and Anderson, K.M.: Distribution on an Isokinetic Gradient of Cells from Dissociated Rat Ventral Prostates of Normal, Castrated and Hormone-Treated Rats. *Proceedings of the American Association for Cancer Research*, 25:813a, 1984.
19. Bhatti, R.A., Ojeda, L., Rubenstein, M., Stuart, R. and Guinan, P.D.: The Effect of Therapy on the Levels of Circulating Immune Complexes in Prostate Cancer. *Proceedings of the American Association for Cancer Research*, 25:956a, 1984.

20. Totonchi, E., Shaw, M.W., Rubenstein, M., Keele, L, Abramowitz, J., Ojeda, L. and Guinan, P.D.: Prostate Cancer in Blacks and Whites. *Clinical Research*, 32:423a, 1984.
21. Rubenstein, M., Bush, I., Abramowitz, J., Shaw, M.W. and Guinan, P.D.: The Effect of Cytosar and DED on the Rejection of Dunning R3327 G Subline Tumor Challenge. *Journal of Urology*, 131:102a, 1984.
22. Bhatti, R.A., Rubenstein, M., Abramowitz, J., Shaw, M.W., Ojeda, L. and Guinan, P.D.: The Effect of Therapy on Circulating Immune Complex Levels in Prostate Cancer. *Journal of Urology*, 131:1208a, 1984.
23. Rubenstein, M., Ablin, R.J., Abramowitz, J., Shaw, M.W., Sharifi, R., Mouli, K. and Guinan, P.D.: Leukocytic Subset Alterations in Prostatic Cancer Patients. *Journal of Urology*, 131:33a, 1984.
24. Ojeda, L., Shaw, M.W., Ray, V., Rubenstein, M., Mouli, K. and Guinan, P.D.: Histologic Changes Following Intravesical BCG and Thiotepa Therapy. *Journal of Urology*, 131:695a, 1984
25. Guinan, P.D., Rubenstein, M., Bhatti, R.A., Abramowitz, J., Shaw, M.W. and Ojeda, L.: An Assessment of Prostate Specific Antigen in Prostate Cancer Patients. *Journal of Urology*, 131:87a, 1984.
26. Rubenstein, M., Shaw, M.W., Ablin, R.J. and Guinan, P.D.: Effect of Hormonal Therapy on Peripheral Blood Leukocytic Subset Distribution in Stage D Prostate Cancer. *Federation Proceedings*, 43:2371a, 1984.
27. Rubenstein, M., Shaw, M.W., Bhatti, R.A., Wang, E., McKiel, C.F. and Guinan, P.D.: A Comparative Study of Immunoregulatory Markers Found in Rats Carrying the Dunning R-3327 G or MAT-LyLu Prostatic Adenocarcinoma Variants. *Journal of Urology*, 133:7a, 1985.
28. Rubenstein, M., Shaw, M.W., Stuart, R., Ablin, R.J., McKiel, C.F. and Guinan, P.D.: The Effect of Hormone Therapy on Peripheral Blood Leukocytic Subset Distributions Found in Stage D Prostate Cancer Patients. *Journal of Urology*, 133:1037a, 1985.
29. Shaw, M.W., Ablin, R.J., McKiel, C.F., Rubenstein, M. and Guinan, P.D.: Prostaglandins in the Tumor Effusions of the Dunning Rat Prostate Adenocarcinoma. *Journal of Urology*, 133:1037a, 1985.
30. Shaw, M, Bhatti, R.A., McKiel, C.F., Ray, P., Habibi, H., Rubenstein, M., Ablin, R. and Guinan, P.D.: Lymphocytic Subset Distribution in Rats Bearing the Dunning Prostatic

Adenocarcinoma. Proceedings of the XXXIII Colloquium: Protides of the Biological Fluids, Brussels, 1985.

31. Rubenstein, M. and Dubin, A.: Prostaglandin E Series Synthesis by Adherent Spleen Cells from Rats Bearing the Dunning R3327 MAT-LyLu Prostatic Tumor. *Journal of Urology*, 135:970a, 1986.
32. Rubenstein, M. and Dubin, A.: The Effect of Cyclophosphamide on Leukocytic Subset Distributions in Rats Carrying the R3327-MAT-LyLu Dunning Prostatic Adenocarcinoma. *Journal of Urology*, 135:971a, 1986.
33. Rubenstein, M.: Kinetic Evaluation of Immunoregulatory Markers Effected by Tumor Development and Cytotoxic Therapy. *Journal of Urology*, 137:48a, 1987.
34. Rubenstein, M. and Dubin, A.: BCG Mediated Immune Suppression Accompanied with Normal T-Cell Subset Distribution. *Journal of Urology*, 137:1044a, 1987.
35. Rubenstein, M., Guinan, P.D., Shaw, M.W., Ray, V. and Dubin, A.: Application of Immunohistologic Staining to Develop a Malignant Index to Aid in Distinguishing Benign from Malignant Prostatic Tissue. *Journal of Urology*, 139:173a, 1988.
36. Shaw, M.W., Ray, V., Rubenstein, M., Birdsall, C., McKiel, C.F. and Guinan, P.D.: Intravesical BCG: What are the Kinetics of the Infiltrating Lymphocytic Subsets. *Journal of Urology*, 139:301a, 1988.
37. Shaw, M.W., Guinan, P.D., Rubenstein, M., McKiel, C.F. and Dubin, A.: Optimal Dosage and Route of Administration of Tumor Necrosis Factor in Treatment of Dunning Prostatic Tumor Bearing Rats. *Journal of Urology*, 139:309a, 1988.
38. Shaw, M.W., Rubenstein, M., Targonski, P., McKiel, C.F. and Guinan, P.D.: The effect of BCG Immunotherapy on Lymphocytic Subset Infiltration in the Dunning R3327 MAT-LyLu Tumor. *Journal of Urology*, 139:460a, 1988.
39. Rubenstein, M., Shaw, M., Ray, V., Targonski, P. and Guinan, P.: Intravesical BCG: What are the Kinetics of the Infiltrating Lymphocytic Subsets? *Journal of Cell Biochemistry Supplement* 12E:140a, 1988.
40. Targonski, P., Rubenstein, M., Shaw, M., Dubin, A., McKiel, C.F. and Guinan, P.: Leukocytic Subset Distributions at Primary and Metastatic Sites of the Dunning MAT LyLu Tumor. *Journal of Urology*, 141:430a, 1989.

41. Grinis, G., Shaw, M., Targonski, P., McKiel, C.F., Dubin, A., Rubenstein, M. and Guinan, P.: Debulking: Does it Impede the Metastatic Process? *Journal of Urology*, 431a, 1989.
42. Rubenstein, M., Shaw, M., Targonski, P., Dubin, A., McKiel, C.F. and Guinan, P.: GM-CSF Induced Restoration of Differentiation Regulatory Characteristics in an Anaplastic Prostatic Tumor. *Journal of Urology*, 141:505a, 1989.
43. Rubenstein, M., Guinan, P.D., Shaw, M., Targonski, P., McKiel, C.F. and Dubin, A.: Coordinate Loss of Growth Regulatory Factors Following Castration of Rats Carrying the Dunning E3327 G Prostatic Tumor. *Journal of Urology* 141:506a, 1989.
44. Johnson, M., Rubenstein, M., Shaw, M. and Guinan, P.: The Effect of Early and Delayed Polyamine Depletion Upon Cytotoxic Chemotherapy in the Dunning Prostate Tumor. *Journal of Urology*, 141:506a, 1989.
45. Stuhldreher, D., Rubenstein, M. and Guinan, P.: Immunopriming of Tumor Infiltrating Lymphocytes in Prostate Cancer. *Proc. Inst. Med. Chicago.*, 43:112, 1990.
46. Siami, P., Stuhldreher, D., Rubenstein, M. and Guinan, P.: Renal Cell Carcinoma at the University of Illinois Hospital. *Proc. Inst. Med. Chgo.*, 43:152, 1990
47. Kester, S., Targonski, P., Rubenstein, M. and Guinan, P.: The effect of Race and Poverty on Prostate Cancer in Chicago. *Proc. Inst. Med. Chgo.*, 43:152, 1990.
48. Rubenstein, M., Shaw, M., Targonski, P., Dubin, A., McKiel, C.F. and Guinan, P.: GM-CSF Induced Differentiation of an Anaplastic Hormone Insensitive Rat Prostatic Tumor. *J. Cancer Res. Clin. Oncol.*, 116:458, 1990.
49. Rubenstein, M., Guinan, P. and Dubin, A.: Immunoregulatory Effects of Arachidonic Acid Metabolites, *J. Cancer Res. Clin. Oncol.*, 116:112, 1990.
50. Targonski, P., Rubenstein, M. and Guinan, P.: The Effect of Socioeconomic Status on Case Fatality Rate in Prostate Cancer. 85th American Urological Association Meeting, 1990.
51. Rubenstein, M., Targonski, P., Shaw, M. and Guinan, P.: Altered Epithelial Growth Factor Receptor Expression Following GM-CSF Therapy and Orchiectomy. 85th American Urological Association Meeting, 1990.
52. Rubenstein, M., Shaw, M., Grinis, G., Targonski, P., Dubin, A., McKiel, C.F. and Guinan, P.: The Effect of Cyto-reductive Surgery and Chemotherapy on Normal Lung and Lung Metastases. 85th American Urological Association Meeting, 1990.

53. Guinan, P., Rubenstein, M., Shaw, M. and McKiel, C.F.: Lymphocyte Traffic in Metastatic Prostate Cancer. 85th American Urological Association Meeting, 1990.
54. Musiala, T., Dubin, A., Shaw, M., Targonski, P., Rubenstein, M., and Guinan, P.: The Effect of Prostatic Tumor Development and Therapy on Serum Leukotriene Levels. 85th American Urological Association Meeting, 1990.
55. Rubenstein, M., Muchnik, S, Shaw, M., Dubin, A. and Guinan, P.: Efficacy of BCG and Cyclophosphamide Immunopriming Prior to Cytokine Mediated Adoptive Immunotherapy. *J. Cell Biochem.*, 15E:80a, 1991.
56. Garber, S.L., Rubenstein, M., Qureshi, Z., Bakir, A.A. and Dunea, G.: The Effect of Pterins on Renal Proximal Tubule Cells in Culture. *J. Amer. Soc. Nephrol.*, 2:773a, 1991.
57. Knudson, G., Ray, P., Sharifi, R., Targonski, P., Rubenstein, M. and Guinan, P.: Bone Metastasis in Prostate Cancer: What is the Pattern of Metastasis? *Proc. Inst. Med. Chgo.*, 44:123, 1991
58. Rubenstein, M., Muchnik, S., Chet, M., Shaw, M., Dubin, A. and Guinan, P.: Immunopriming May Enhance Effectiveness of Adoptive Immunotherapy. 86th American Urologic Association Meeting, 1991.
59. Rubenstein, M., Muchnik, S., Chet, M., Shaw, M., Dubin, A. and Guinan, P.: Effect of BCG on Helper/Suppressor-T Cell Ratios of Tumor Infiltrating Lymphocytes Isolated from Treated and Untreated Tumors. 86th American Urologic Association Meeting, 1991.
60. Stuhldreher, D., Muchnik, S., Shaw, M., Rubenstein, M. and Guinan, P.: Thoracic Duct Lymphocytes as Surrogates for Tumor Infiltrating Lymphocytes. 86th American Urologic Association Meeting, 1991.
61. Stuhldreher, D., Targonski, P., Frank, W., Ray, P., Rubenstein, M. and Guinan, P.: Is Nephrectomy Justified in Patients with Stage IV Disease? *Proc. Inst. Med. Chgo.*, 44:, 1991.
62. Stuhldreher, D., Frank, W., Targonski, P., Ray, P., Rubenstein, M. and Guinan, P.: Tumor Size as it Relates to Staging in Renal Cell Carcinoma, *Proc. Inst. Med. Chgo.*, 44:87, 1991.
63. Rubenstein, M., Muchnik, S., Shaw, M., Dunea, G and Guinan, P.: Antisense Oligonucleotide Treatment of Prostate Cancer. *J. Cell. Biochem.*, 198A, 1992.

64. Rubenstein, M., Muchnik, S., Shaw, M., Dunea, G. and Guinan, P.: Histologic Evaluation of PC3 Tumors Treated with Antisense Oligonucleotides, *J. Urol.*, 475a, 1993.
65. Saffrin, R., Rubenstein, M., Ray, P. and Guinan, P.: The Impact of Transrectal Ultrasound on Stage Migration at Diagnosis: Patterns of Care in Prostate Cancer 1985-1990. *J. Urol.*, 288A, 1993.
66. Bridges, P., Guinan, P., Muchnik, S., Shaw, M., Mirochnik, Y. and Rubenstein, M.: Growth Enhancement by Orthotopic Placement of the Dunning Tumor. Society for Basic Urology Research, Spring Symposium, 57, 1994.
67. Rubenstein, M., Muchnik, S., Dunea, G. and Guinan, P.: Growth Factor Deprivation Therapy of Hormone Insensitive PC-3 Prostate Tumors Utilizing Antisense Oligonucleotides. A Special Meeting of the American Association for Cancer Research on Growth Factors, Development and Cancer, 18, 1994.
68. Rubenstein, M., Muchnik, S., Dunea, G. and Guinan, P.: Growth Factor Deprivation Therapy Utilizing Antisense Oligonucleotides in the Treatment of PC-3 and LNCaP Tumors Growing in Athymic Nude Mice. Society for Basic Urology Research, Spring Symposium, 47, 1994
69. Rubenstein, M., Guinan, P., Muchnik, S., Dunea, G. and McKiel, C.F.: In Vivo Antisense Oligonucleotide Treatment of Hormone-Sensitive and Insensitive Human Prostate Tumors growing in Athymic Nude Mice. *Societe Internationale D'Urologie*, 85, 1994.
70. Brecklin C, Muchnik S, Jaffer F, Rubenstein M, Dunea G, Arruda JAL: Renal IGF-1 expression in unilateral ureteral obstruction. *Clin Res* 1994; 42:219A.
71. Brecklin CS, Garber SL, Mirochnik Y, Lema R, Rubenstein M, Arruda JAL, and Dunea G. Renal IGF-I expression in metabolic acidosis. *Am Soc Nephrol* 1994; 27: 689.
72. Guinan, P., Shaw, M. Bridges, P., DiDomenico, D., Brown, J. and Rubenstein, M: Bropiramine as Neoadjuvant Therapy with Prostatectomy in the Dunning Rat Prostate Cancer. *Can. J. Infect. Dis.*, 6:396a, 1995.
73. Rubenstein, M., Mirochnik, Y., McKiel, C.F. and Guinan, P.: Antisense Oligonucleotide Induced Growth Factor Deprivation in PC-3 Cells Enhances Bel-2 Expression. *J. Urol*, 153:270a, 1995.

74. DiDomenico, D., Brown, J., Shaw, M., Rubenstein, M. and Guinan, P.: Intralesional AD-32 is Efficacious in a Prostate Cancer Model. Proceedings AACR 37:303a, 1996.
75. Lievano, G., Rubenstein, M., Shaw, M. and Guinan, P.: Bropiramine as Neoadjuvant Therapy is Effective in a Prostate Cancer Model. J. Urol. 155:356a, 1996.
76. Rubenstein, M., Mirochnik, Y., McKiel, C.F. and Guinan, P.: Antisense Oligonucleotide Intralesional Therapy of Human PC-3 Prostate Tumors Carried in Athymic Nude Mice. J. Urol. 155:602a, 1996.
77. Rubenstein, M., Mirochnik, Y. and Guinan, P.: Delivery of Biotinylated Agents to Prostate Cancer Cells Utilizing Hybrid Monoclonal Antibodies. Proceedings AACR 37:303a, 1996.
78. Rubenstein, M., Mirochnik, Y. and Guinan, P.: Growth Factor Deprivation Therapy of Hormone Insensitive Breast Cancer Utilizing Antisense Oligonucleotides. Cancer Detect. and Prevent. 20:430a, 1996.
79. Rubenstein, M., Sharifi, R., Ray, V., Lievano, G., Mirochnik, Y., Shaw, M. and Guinan, M.: Androgen Blockade Prior to Radical Prostatectomy: Can Response be Predicted? Cancer Detect. and Prevent. 20:515a, 1996.
80. Rubenstein, M., Sharifi, R., Ray, V., Lievano, G., Mirochnik, Y., Shaw, M. and Guinan, P.: Radical Prostatectomy After Androgen Blockade: Are Marker and Morphologic Changes Significant? Cancer Detect. and Prevent. 20:516a, 1996.
81. Domenico, D., Brown, J., Shaw, M., Sharifi, R., Ray, V., Rubenstein, M. and Guinan, P.: The Effect of Androgen Deprivation on Malignant and Benign Prostate tissue. J. Urol. 122a, 1997.
82. Rubenstein, M., Glick, R., Lichtor, T., Mirochnik, Y. and Guinan, P.: Treatment of the T98G Glioblastoma Cell Line with Antisense Oligonucleotides Directed Towards mRNA Encoding Transforming Growth Factor- α and the Epidermal Growth Factor Receptor. Proceedings AACR 38:10a, 1997.
83. Uzoaru, I., Rubenstein, M. and Guinan, P.: Histologic, Proliferative and Karyotypic Evaluation of 42 Patients with Stage IV Prostate Cancer. Proceedings AACR 38:542a, 1997.
84. Frank, W., Shaw, M., Chet, A., Rubenstein, M. and Guinan, P.: BCG Treatment Increases PGF2 levels in Dunning AT-3 Prostate Murine Tumor. Proceedings AACR 39:586a, 1998.

85. Quinan, P., Shott, S., Sharifi, R., Kennedy, J., Ray, V., Shaw, M. and Rubenstein, M.: Predicting Response in Hormone Downstaged Patients Prior to Radical Prostatectomy. Proceedings AACR 39:15a, 1998.
86. Rubenstein, M., Glick, R., Lichtor, T., Mirochnik, Y. and Guinan, P.: Dose response and Cellular Uptake of Antisense Oligonucleotides to Transforming Growth Factor-alpha and the Epidermal Growth Factor Receptor of the T98G Glioblastoma. Proceedings AACR 39:416a, 1998.
87. Guinan, P., Rubenstein, M., Shaw, M., McKiel, C.F. and Elterman, L.: African-Americans Receive Therapy for Cure of Prostate Cancer at Rates Similar to Whites. J. Urol. 161:357a, 1999.
88. Rubenstein, M., Mirochnik, Y. and Guinan, P.: Delivery of Antisense Oligonucleotides to Prostate Cancer by Monoclonal Vehicles In In Vivo and In Vitro Models. Proceedings AACR 40:586a, 1999.
89. Rubenstein, M., Shaw, M.W., Slobodskoy, L., Mirochnik, Y., Glick, R., Lichtor, T., Shaw, M.M., Robertson, N., Garcia, V., Frazier, L. and Guinan, P.: Establishment of the T98G Glioblastoma Tumor in Athymic Nude Mice Utilizing Matrigel and Orthotopic Implantation. Proceedings AACR 40:717a, 1999.
90. Rubenstein, M., Mirochnik, Y. and Guinan, P.: Specific Delivery of Oligonucleotides to Prostate Tumors Utilizing Two Monoclonal Antibody Derived Vehicles. Eur. Urol. 36:516a, 1999.
91. Rubenstein, M., Mirochnik, Y., McKiel, C.F. and Guinan, P.: Evaluation of PSA and PSMA as Targets for Specific Delivery of Antisense Oligonucleotides to LNCaP Prostate Tumor Cells Utilizing Two Monoclonal Antibody Derived Vehicles. BJU International 86:supplement 64a, 2000.
92. Rubenstein, M., Glick, R., Lichtor, T., Mirochnik, Y. and Guinan, P.: Decreased EGFR Expression and Growth of the Human Derived T98G Glioblastoma Following Treatment with Antisense Oligonucleotides Directed against EGFR. Proceedings AACR 41:644a, 2000.
93. Streisand, S., Shaw, M., Rubenstein, M. and Guinan, P.: African-Americans are not Receiving Treatment for Cure for Prostate Cancer at Rates Comparable to Whites. J. Urol. 163:290a, 2000.
94. Rubenstein, M., Mirochnik, Y. and Guinan, P.: Enhanced Cellular Uptake and Use of Specific Delivery Vehicles in Treating Prostate Cancer with Antisense Oligonucleotides. Proceedings AACR 42:377a, 2001.

95. Rubenstein, M., Mirochnik, Y., Bremer, E., George, D., Freilich, L. and Guinan, P.: Inhibitory Effect of Antisense Oligonucleotides Targeting Epidermal Growth Factor Receptor May Not be Related to Changes in mRNA Levels in Human Prostate Carcinoma Cells. *Proceedings AACR* 43:590a, 2002.
96. Rubenstein, M., Mirochnik, Y., Slobodskoy, L. and Guinan, P.: Antisense oligonucleotide therapy against prostate cancer is altered by backbone modification, and oligo pretreatment can enhance efficacy of taxol. *Proceedings AACR* 44:849a, 2003.
97. Rubenstein, M., Mirochnik, Y., Slobodskoy, L. and Guinan, P.: Inhibition of PC-3 prostate cancer cell growth in vitro using both antisense oligonucleotides and taxol. *J. Urol.* 169 (supplement):222a, 2003.
98. Rubenstein, M., Tsui, P., Guinan, P.: Antisense oligonucleotide therapy in combination with taxol, cytoxan and mitoxantrone in the treatment of prostate cancer. *BJU* 94 (supplement 2): 93a, 2004.
99. Rubenstein, M., Tsui, P., Ting, M., Ting, K., Guinan, P.: siRNA directed against EGFR has comparable efficacy to a first generation antisense oligonucleotide in combination therapy against the PC-3 prostate tumor line. *Proceedings AACR* 46:136a, 2005.
100. Rubenstein, M., Tsui, P., Guinan, P.: Development of bispecific oligonucleotides with multiple binding sites for the treatment of prostate tumors and their applicability to combination therapy. *Proceedings AACR* 47:516a, 2006.
101. Rubenstein, M., Tsui, P., Christensen, K.A., Guinan, P.: Effect of bispecific antisense oligos on prostate cancer cell growth. *Journal of Clin. Oncol. ASCO Annual Meeting Proceedings* 25 (supplement): 14034a, 2007.
102. Rubenstein, M., Tsui, P., Guinan, P.: Treatment of MCF-7 breast cancer cells with mono- and bispecific antisense oligonucleotides. *Journal of Clin. Oncol. ASCO Annual Meeting Proceedings* 26: (supplement): 14660a, 2008.